- Home
- SIF vs TNXP Comparison
SIF vs TNXP Comparison
Compare SIF & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIF
- TNXP
- Stock Information
- Founded
- SIF 1913
- TNXP 2007
- Country
- SIF United States
- TNXP United States
- Employees
- SIF N/A
- TNXP N/A
- Industry
- SIF Office Equipment/Supplies/Services
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- SIF Industrials
- TNXP Health Care
- Exchange
- SIF Nasdaq
- TNXP Nasdaq
- Market Cap
- SIF 21.7M
- TNXP 19.5M
- IPO Year
- SIF N/A
- TNXP N/A
- Fundamental
- Price
- SIF $3.88
- TNXP $0.20
- Analyst Decision
- SIF
- TNXP Strong Buy
- Analyst Count
- SIF 0
- TNXP 2
- Target Price
- SIF N/A
- TNXP $53.50
- AVG Volume (30 Days)
- SIF 18.7K
- TNXP 51.5M
- Earning Date
- SIF 12-27-2024
- TNXP 11-12-2024
- Dividend Yield
- SIF N/A
- TNXP N/A
- EPS Growth
- SIF N/A
- TNXP N/A
- EPS
- SIF N/A
- TNXP N/A
- Revenue
- SIF $101,482,000.00
- TNXP $11,291,000.00
- Revenue This Year
- SIF N/A
- TNXP $62.53
- Revenue Next Year
- SIF N/A
- TNXP $26.17
- P/E Ratio
- SIF N/A
- TNXP N/A
- Revenue Growth
- SIF 25.24
- TNXP 183.05
- 52 Week Low
- SIF $2.87
- TNXP $0.12
- 52 Week High
- SIF $5.96
- TNXP $22.08
- Technical
- Relative Strength Index (RSI)
- SIF 53.59
- TNXP 69.43
- Support Level
- SIF $3.50
- TNXP $0.13
- Resistance Level
- SIF $3.68
- TNXP $0.28
- Average True Range (ATR)
- SIF 0.18
- TNXP 0.02
- MACD
- SIF 0.05
- TNXP 0.01
- Stochastic Oscillator
- SIF 62.16
- TNXP 49.47
About SIF SIFCO Industries Inc.
SIFCO Industries Inc is engaged in the production of forgings and machined components for the Aerospace and Energy, Defense and Commercial Space markets. Its processes and services include forging, heat-treating and machining. It serves original equipment manufacturers (OEM) as well as aftermarket customers. Its products are made of steel, stainless steel, titanium and aluminium and include OEM and aftermarket components for aircraft and industrial gas turbine engines, steam turbine blades, structural airframe components, aircraft landing gear components, aircraft wheels and brakes, critical rotating components for helicopters and industrial products. Substantial revenue is derived from North America as well as operates in Europe.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.